{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008500","form_type":"8-K","ticker":"HSCS","cik":"0001468492","company_name":"HeartSciences Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.122920+00:00","generated_at":"2026-06-18T00:25:55.210873+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"HeartSciences Q3 no revenue, $1.9M cash; progresses MyoVista FDA clearance, adopts equity plan","bullets":["No meaningful Q3 FY2023 revenues; cash and equivalents $1.9M as of Jan 31, 2023.","MyoVista pivotal validation study enrollment progressing for FDA De Novo resubmission; additional enrichment patients enrolled.","Board adopted 2023 Equity Incentive Plan, subject to stockholder approval, covering employees, directors, and consultants.","Collaboration with Rutgers University for AI-based ECG algorithms; patent portfolio now 40 (9 U.S., 31 international).","Appointed microcap veteran David R. Wells to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008500","json":"https://secwatch.observer/filing/0000950170-23-008500.json","markdown":"https://secwatch.observer/filing/0000950170-23-008500.md","text":"https://secwatch.observer/filing/0000950170-23-008500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/0000950170-23-008500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/hscs-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:25:55.210873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a231ec0b68d5ff92ac27d3a61641b00e03fdcbbb","claim":"HeartSciences Inc. reported the fiscal 2023 third quarter ended January 31, 2023 results: revenue no meaningful revenues.","evidence_excerpt":"Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (\"HeartSciences\" or the \"Company\") , a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/0000950170-23-008500-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal 2023 third quarter ended January 31, 2023"},{"label":"Revenue","value":"no meaningful revenues"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}